Effect of SGLT in Type 2 Diabetes and Gastric Bypass Surgery - A Narrative Review

Abstract

Body fat is regulated by a complex neuroendocrine system, making it difficult to maintain weight loss achieved via caloric restriction. Bariatric surgery produces greater weight loss and weight loss that is more durable than caloric restriction, and therefore is currently the most effective therapy for obesity. Sodium-glucose-co-transporter inhibitors are glucose lowering drugs that reduces plasma glucose levels by inhibiting glucose and sodium reabsorption in the kidneys, resulting in glycosuria. Sleeve gastrectomy is one such bariatric surgical procedure that involves the creation of a reduced stomach lumen along the lesser curvature of the stomach through the removal of gastric tissues along the greater curvature from the fundus to the antrum. Stomach capacity is typically reduced 80% or more, and the intestine remains intact. This procedure produces dramatic weight loss in humans and in rodents. In fact, recent reports indicate that its efficacy is close to that of the more common Roux-en Y gastric bypass. There are many diverse factors on which operative mortality of bariatric surgery depends such as facility related, surgeon related, followed by patient and procedure-related. To minimize operative mortality, specific factors were considered for the specific patients. As a result, to treat type 2 diabetes in association with obesity, slightly obese patients or overweight patients were treated with conventional bariatric procedures worldwide. For the management of morbidity obese diabetic patients, there is no single or standard procedure. Mahmood. Effect of SGLT in type 2 diabetes and gastric bypass surgery -a narrative review.